Sangamo Therapeutics (SGMO) Announces EMA Recommendation Of Orphan Medicinal Product Designation For Investigational Genome Editing Treatments For MPS I And MPS II
Tweet Send to a Friend
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
